Coeptis Therapeutics (NASDAQ:ZSQR) Trading Down 7% – What’s Next?

Coeptis Therapeutics Holdings, Inc. (NASDAQ:ZSQR)’s stock price traded down 7% during mid-day trading on Monday . The stock traded as low as $10.10 and last traded at $10.22. Approximately 155,485 shares were traded during mid-day trading, a decline of 23% from the average session volume of 201,585 shares. The stock had previously closed at $10.99.

Wall Street Analyst Weigh In

Separately, Wall Street Zen cut shares of Coeptis Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, June 13th. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat, the stock has an average rating of “Sell”.

Coeptis Therapeutics Stock Up 0.1%

The company has a debt-to-equity ratio of 0.01, a current ratio of 3.25 and a quick ratio of 3.25. The firm has a market capitalization of $565.73 million, a P/E ratio of -4.37 and a beta of -0.25. The firm’s fifty day moving average price is $12.01 and its 200-day moving average price is $12.59.

Coeptis Therapeutics (NASDAQ:ZSQR) last released its earnings results on Thursday, May 14th. The company reported ($0.65) earnings per share for the quarter. The firm had revenue of $0.11 million during the quarter. Coeptis Therapeutics had a negative return on equity of 92.29% and a negative net margin of 810.04%.

Institutional Investors Weigh In On Coeptis Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of ZSQR. Yorkville Advisors Global LP purchased a new stake in shares of Coeptis Therapeutics during the third quarter valued at $140,000. Geode Capital Management LLC lifted its stake in Coeptis Therapeutics by 12.6% during the fourth quarter. Geode Capital Management LLC now owns 42,097 shares of the company’s stock valued at $600,000 after buying an additional 4,721 shares in the last quarter. Steward Partners Investment Advisory LLC boosted its holdings in shares of Coeptis Therapeutics by 100.0% in the fourth quarter. Steward Partners Investment Advisory LLC now owns 5,000 shares of the company’s stock worth $71,000 after buying an additional 2,500 shares during the period. State Street Corp increased its position in shares of Coeptis Therapeutics by 35.0% in the fourth quarter. State Street Corp now owns 26,830 shares of the company’s stock worth $382,000 after acquiring an additional 6,962 shares in the last quarter. Finally, Marshall Wace LLP acquired a new stake in shares of Coeptis Therapeutics during the fourth quarter valued at approximately $259,000. 13.88% of the stock is owned by institutional investors and hedge funds.

Coeptis Therapeutics Company Profile

Coeptis Therapeutics Holdings, Inc, a biopharmaceutical company, develops cell therapy platforms for patients with cancer. Its product portfolio consists of CD38-GEAR-NK, a cell therapy for the treatment of CD38-related cancers, including multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia; SNAP-CAR, a CAR T cell therapy platform co-administered with tagged, tumor-specific antibodies to potentially target different tumor types, including hematological malignancies and solid tumors; and CD38-Diagnostic, an in vitro screening tool to analyze if cancer patients might be appropriate candidates for anti-CD38 mAb therapy.